

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**Applicants:** David M. Center, et al.**Examiner:** Unassigned**Serial No.:** Unassigned**Art Unit:** Unassigned**Filing Date:** Herewith**Docket:** 12861A**For:** IL-16 ANTAGONISTS**Date:** August 15, 2001Assistant Commissioner for Patents
Washington, DC 20231**PRELIMINARY AMENDMENT**

Sir:

Prior to examination, please amend the above-identified patent application as follows:

IN THE SPECIFICATION:

Page 1, after the title, please insert the following:

CERTIFICATE OF MAILING BY "EXPRESS MAIL"**"Express Mail" mailing label number:** EL895322645US**Date of Deposit:** August 15, 2001

I hereby certify that this New Patent Application and Fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

Dated: August 15, 2001
Mishelle Mustafa

--CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a divisional of application Serial Number
09/368,632 filed August 5, 1999.--

IN THE CLAIMS:

Please cancel Claims 1-20 and 22-28 before calculating the filing fee of this divisional application.

Please amend Claim 21 as follows:

21. (Amended) A pharmaceutical composition comprising the antibody of
any one of Claims 29-35.

Please add the following new Claims:

29. (New) An antibody directed against an isolated IL-16 antagonist peptide
consisting of CLLS (SEQ ID NO:2).

30. (New) An antibody directed against an isolated IL-16 antagonist peptide
consisting of any one of WQCLLS, WQALLS, VVQVVVA or VKQVVVA.

31. (New) An antibody directed against an isolated IL-16 antagonist peptide
consisting of GMWQLLS (SEQ ID NO:13).

32. (New) An antibody directed against an isolated IL-16 antagonist peptide
consisting of GMWQCLLSDSGQVLLE (SEQ ID NO:12).

33. (New) An antibody directed against an isolated IL-16 antagonist peptide
consisting of TGLWQCLLSEGD (SEQ ID NO:14).

34. (New) An antibody directed against an isolated IL-16 antagonist peptide
consisting of VSEEQKVVQVVVA (SEQ ID NO:15).

35. (New) An antibody directed against an isolated IL-16 antagonist peptide
comprising Xaa₁-L-L-Xaa₂ wherein Xaa₁ and Xaa₂ is any amino acid (SEQ ID NO:1).

REMARKS

It is respectfully requested that this Preliminary Amendment be entered in this application prior to examination. Early and favorable consideration is requested.

Respectfully submitted,



Frank S. DiGiglio
Registration No. 31,346

SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343

PIB:bb

105160-42063650

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

Page 1, after the title, please insert the following:

--CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a divisional of application Serial Number
09/368,632 filed August 5, 1999.--

IN THE CLAIMS:

Please cancel Claims 1-20 and 22-28 before calculating the filing fee of this divisional application.

Please amend Claim 21 as follows:

21. (Amended) A pharmaceutical composition comprising the antibody of
[Claim 19] any one of Claims 29-35.

Please add the following new Claims:

29. (New) An antibody directed against an isolated IL-16 antagonist peptide
consisting of CLLS (SEQ ID NO:2).

30. (New) An antibody directed against an isolated IL-16 antagonist peptide
consisting of any one of WQCLLS, WQALLS, VVQVVA or VKQVVA.

31. (New) An antibody directed against an isolated IL-16 antagonist peptide
consisting of GMWQLLS (SEQ ID NO:13).

32. (New) An antibody directed against an isolated IL-16 antagonist peptide
consisting of GMWQCLLSDSGQVLLE (SEQ ID NO:12).

33. (New) An antibody directed against an isolated IL-16 antagonist peptide consisting of TGLWQCLLSEGD (SEQ ID NO:14).

34. (New) An antibody directed against an isolated IL-16 antagonist peptide consisting of VSEEQKVQVVA (SEQ ID NO:15).

35. (New) An antibody directed against an isolated IL-16 antagonist peptide comprising Xaa₁-L-L-Xaa₂ wherein Xaa₁ and Xaa₂ is any amino acid (SEQ ID NO:1).

FOIA b7 - 42666660